Rita Mágenheim

542 total citations
10 papers, 345 citations indexed

About

Rita Mágenheim is a scholar working on Cardiology and Cardiovascular Medicine, Obstetrics and Gynecology and Molecular Biology. According to data from OpenAlex, Rita Mágenheim has authored 10 papers receiving a total of 345 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Cardiology and Cardiovascular Medicine, 3 papers in Obstetrics and Gynecology and 2 papers in Molecular Biology. Recurrent topics in Rita Mágenheim's work include Pregnancy and preeclampsia studies (2 papers), Barrier Structure and Function Studies (2 papers) and Cardiovascular Issues in Pregnancy (2 papers). Rita Mágenheim is often cited by papers focused on Pregnancy and preeclampsia studies (2 papers), Barrier Structure and Function Studies (2 papers) and Cardiovascular Issues in Pregnancy (2 papers). Rita Mágenheim collaborates with scholars based in United States, Hungary and United Kingdom. Rita Mágenheim's co-authors include Carla Oliveíra, Thierry Frébourg, D. Gareth Evans, Svetlana Bajalica‐Lagercrantz, Nándor Gábor Than, János Rigó, Zoltán Papp, Beáta Hargitai, Adi L. Tarca and István Sziller and has published in prestigious journals such as Journal of Clinical Oncology, Diabetologia and Journal of Clinical Pathology.

In The Last Decade

Rita Mágenheim

10 papers receiving 336 citations

Peers

Rita Mágenheim
K. Oliva Australia
Jingchun Luo United States
Olivier Marpeau France
Florian Klinglmüller Austria
J. Mazurka Canada
Valentina Zanfagnin United States
Ana Teresa Martins Portugal
A. Athanassiades Greece
Eirini Papadopoulou Greece
N. Sakuragi Japan
K. Oliva Australia
Rita Mágenheim
Citations per year, relative to Rita Mágenheim Rita Mágenheim (= 1×) peers K. Oliva

Countries citing papers authored by Rita Mágenheim

Since Specialization
Citations

This map shows the geographic impact of Rita Mágenheim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rita Mágenheim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rita Mágenheim more than expected).

Fields of papers citing papers by Rita Mágenheim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rita Mágenheim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rita Mágenheim. The network helps show where Rita Mágenheim may publish in the future.

Co-authorship network of co-authors of Rita Mágenheim

This figure shows the co-authorship network connecting the top 25 collaborators of Rita Mágenheim. A scholar is included among the top collaborators of Rita Mágenheim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rita Mágenheim. Rita Mágenheim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Yap, Timothy A., Emiliano Calvo, Víctor Moreno, et al.. (2025). First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors.. Journal of Clinical Oncology. 43(16_suppl). 2501–2501. 1 indexed citations
2.
Beaverson, Katherine, Daria Julkowska, Annemieke Aartsma‐Rus, et al.. (2023). The IRDiRC Chrysalis Task Force: making rare disease research attractive to companies. PubMed Central. 4. 6 indexed citations
3.
Papadopoulos, Kyriakos P., Mustapha Tehfé, Albiruni Ryan Abdul Razak, et al.. (2023). A phase I/II dose escalation and expansion trial to evaluate safety and preliminary efficacy of BNT141 in patients with claudin-18.2-positive solid tumors.. Journal of Clinical Oncology. 41(16_suppl). TPS2670–TPS2670. 11 indexed citations
4.
Frébourg, Thierry, et al.. (2020). Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes. European Journal of Human Genetics. 28(10). 1379–1386. 170 indexed citations
5.
Horváth, E, Rita Mágenheim, Nóra Béres, et al.. (2018). Oxidative‐Nitrative Stress and Poly (ADP‐Ribose) Polymerase Activation 3 Years after Pregnancy. Oxidative Medicine and Cellular Longevity. 2018(1). 1743253–1743253. 5 indexed citations
6.
Mágenheim, Rita, et al.. (2017). The Relationship between 25-hydroxyvitamin D Levels, Insulin Sensitivity and Insulin Secretion in Women 3 Years after Delivery. Canadian Journal of Diabetes. 41(6). 621–627. 4 indexed citations
7.
8.
Horváth, E, Rita Mágenheim, Gabriella Vácz, et al.. (2009). Nitrative stress and poly(ADP-ribose) polymerase activation in healthy and gestational diabetic pregnancies. Diabetologia. 52(9). 1935–1943. 37 indexed citations
9.
Than, Nándor Gábor, Rita Mágenheim, Bálint Nagy, et al.. (2008). Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 453(4). 387–400. 89 indexed citations
10.
Boronkai, Árpád, Nándor Gábor Than, Rita Mágenheim, et al.. (2004). Extremely high maternal alkaline phosphatase serum concentration with syncytiotrophoblastic origin. Journal of Clinical Pathology. 58(1). 72–76. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K. Oliva Breakdown of academic impact, for papers by Jingchun Luo Breakdown of academic impact, for papers by Olivier Marpeau Breakdown of academic impact, for papers by Florian Klinglmüller Breakdown of academic impact, for papers by J. Mazurka Breakdown of academic impact, for papers by Valentina Zanfagnin Breakdown of academic impact, for papers by Ana Teresa Martins Breakdown of academic impact, for papers by A. Athanassiades Breakdown of academic impact, for papers by Eirini Papadopoulou Breakdown of academic impact, for papers by N. Sakuragi
Rankless by CCL
2026